Nouvelles études dans le diabète de type 2 : le point de vue du cardiologue

Type 2 diabetes (T2D) is a risk factor and a severe disease also. Insulin resistance syndrome is a situation to be screened and treated as early as possible. When DT2 is present, nobody knows if this is indeed primary or secondary cardiovascular prevention. Recent randomized controlled trials have analyzed hypoglycemic drugs in severe cases in patients having cardiovascular diseases and a long history of hyperglycemia exposure. Nevertheless, in the LEADER and EMPA-REG OUTCOME outcome studies, a superiority of the new hypoglycemic agents was noticed in comparison with placebo, and this result was associated with a decrease of cardiovascular events. The safety of the new hypoglycemic drugs is now demonstrated and the cardiovascular benefits of these new drugs have nearly been shown. Cardiologists might now screen and treat appropriately T2D in order to decrease acute coronary syndrome incidence.